The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
BUSINESS
Sales of DPP-4 Inhibitors on Track to Reach ¥100 Bil. this Fiscal Year
Dipeptidyl peptidase-4 (DPP-4) inhibitors were expected to penetrate the market fairly quickly, but it could hardly have been predicted that they would create a ¥100 billion market in barely two years. Januvia/Glactiv (sitagliptin) debuted in December 2009, followed by Equa…
To read the full story
BUSINESS
- Takeda Returns to Core Profit Growth, CEO Confident in Trajectory
October 30, 2026
- Tanabe Files Lymphoma ADC in Japan, Taps Nippon Shinyaku for Sales
October 30, 2026
- Bayer Launches Hyrnuo in Japan for HER2-Mutated Lung Cancer
October 30, 2026
- Kissei Cuts H1 Profit Outlook on Tavneos Approval Revocation Risk
October 29, 2026
- Nxera Licenses Fabry Disease Drug from Idorsia
October 29, 2026
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…